無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催
癌バイオマーカーの世界市場 〜2022年：種類 (タンパク質バイオマーカー／遺伝子バイオマーカー)・腫瘍・プロファイリング技術・用途 ・地域別
Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application - Global Forecast to 2022
|出版日||ページ情報||英文 251 Pages
|癌バイオマーカーの世界市場 〜2022年：種類 (タンパク質バイオマーカー／遺伝子バイオマーカー)・腫瘍・プロファイリング技術・用途 ・地域別 Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application - Global Forecast to 2022|
|出版日: 2017年10月05日||ページ情報: 英文 251 Pages||
世界の癌バイオマーカー市場は、2017年から2022年にかけて12.2%のCAGR (年間複合成長率) で推移し、2017年の115億3000万米ドルから、2022年には204億8000万米ドルの規模に成長すると予測されています。
当レポートでは、世界の癌 (腫瘍) バイオマーカーの市場について分析し、技術的概要や市場の基本的構造・最新動向、主な市場促進・阻害要因、市場規模の動向見通し (今後6年間分)、腫瘍別・種類別・技術別・用途別・地域別の詳細動向、市場競争の状態、今後の技術開発・市場発展の方向性、主要企業のプロファイルなどを調査・考察しております。
"Global cancer biomarkers market projected to grow at CAGR of 12.2%"
The global cancer biomarkers market is projected to reach USD 20.48 billion by 2022 from USD 11.53 billion in 2017, at a CAGR of 12.2% from 2017 to 2022.
Over the years, the cancer biomarkers market has evolved significantly owing to the rising prevalence of cancer, advancements in omics technologies, increasing healthcare expenditure, growth in R&D funding from government and private bodies, and rising demand for personalized medicine in cancer therapies. However, an unfavorable regulatory and reimbursement scenario and the high capital investments required for biomarker development and validation are some factors expected to restrain the market.
The cancer biomarkers market on the basis of cancer type is classified into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-hodgkin's lymphoma, kidney, and other cancers. The lung cancer segment is expected to register the highest CAGR during the forecast period. The increasing company focus on research on lung cancer biomarkers is the key driver for this market. Increased understanding of the morphology of lung carcinogenesis, development of the high-throughput techniques for biomarker discovery, and increased focus on early detection of cancer are propelling the growth of this market.
North America (comprising the US and Canada) is expected to account for the largest share of the global cancer biomarkers market in 2017. The large share of this geographic segment is mainly attributed to the increasing government support for discovery and development of biomarkers, increasing demand for personalized medicine, adoption of advanced omics technologies for biomarker discovery, and rising use of biomarkers in drug discovery and development by pharmaceutical companies in that region. While the APAC region is expected to register the highest CAGR during the forecast period. The APAC cancer biomarkers market, particularly in China, Japan, and India is expected to witness high growth during the forecast period.
Break of primary participants was as mentioned below:
Major players in this market that are profiled in the report includes Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson (US), Hologic (US), Danaher (US), and Shimadzu (Japan).
From an insight perspective, this research report focuses on qualitative data, market size, and growth of various segments and subsegments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and challenges). The report also offers market sizes and data on the growth of various segments of the industry. It focuses on emerging and high-growth segments, and high-growth regions. The competitive landscape covers growth strategies adopted by industry players in the last three years. The company profiles comprise basic views on key players in the cancer biomarkers market and the product portfolios, developments, and strategies adopted by market players to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output to remain successful.
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.
The report provides insights on the following pointers:
*Business Overview, Strength of Product Portfolio, Business Strategy Excellence, Recent Developments might not be captured in case of unlisted companies.